Free cash flow was negative in most recent quarters and turned positive only to $46.6M (a 3.1% margin) in the latest quarter, while operating cash flow to net income ratios ranged from -3.19 to 1.43, indicating erratic conversion that investors should monitor.
Agilon Health, Inc. (AGL) cash flow statement — 7-year operating, investing & financing cash flows
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 |
|---|
| Cash from Operations | -4.23M | -105.76M | -57.78M | -156.2M | -130.81M | -148.16M | -53.2M | -103.86M |
| Operating CF Margin % | - | -1.78% | -0.95% | -3.62% | -5.48% | -9.74% | -4.37% | -13.07% |
| Operating CF Growth % | 260.51% | -83.05% | 63.01% | -19.41% | 11.71% | -178.47% | 48.77% | - |
| Net Income | -106.04M | -391.35M | -260.1M | -262.8M | -106.86M | -406.79M | -60.05M | -282.74M |
| Depreciation & Amortization | 27.36M | 28.59M | 24.46M | 20.16M | 13.77M | 14.67M | 14.1M | 41.41M |
| Stock-Based Compensation | 58.47M | 49.12M | 50.66M | 69.33M | 28.38M | 292.39M | 6.69M | 5.22M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 532K | -3.23M | -2.81M | -16.18M |
| Other Non-Cash Items | 48.77M | 18.4M | -3.38M | 27.18M | -7.19M | 9.82M | -17.6M | 115.24M |
| Working Capital Changes | -51.73M | 189.47M | 130.59M | -10.07M | -59.44M | -55.02M | 6.47M | 33.18M |
| Change in Receivables | 0 | 344.58M | -74.58M | 0 | -204.17M | -149.04M | -59.38M | -23.28M |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 149.04M | 0 | 0 |
| Change in Payables | 0 | -87.48M | 198.58M | 473.61M | 173.45M | 95.7M | 67.31M | 38.26M |
| Cash from Investing | 79.59M | 88.61M | 139.89M | -44.02M | -444.39M | -90.51M | 22.07M | -5.06M |
| Capital Expenditures | -15.46M | -13.24M | -13.25M | -15.83M | -15.43M | -13.43M | -2.35M | -3.91M |
| CapEx % of Revenue | 0.26% | 0.22% | 0.22% | 0.37% | 0.65% | 0.88% | 0.19% | 0.49% |
| Acquisitions | 0 | 0 | 0 | -43.06M | 500K | -1.34M | 26.2M | 0 |
| Investments | - | - | - | - | - | - | - | - |
| Other Investing | -5.99M | -31.87M | -41.77M | -34.51M | -23.75M | -75.74M | -1.79M | -1.15M |
| Cash from Financing | -657K | -2.99M | -2.58M | -193.13M | 28.06M | 1.15B | 24.62M | 176.3M |
| Debt Issued (Net) | -3.5M | 0 | -3.75M | -5M | -5M | -19.9M | -3.04M | -3.59M |
| Equity Issued (Net) | 4.46M | -2.99M | 1.17M | -200M | 33.06M | 1.19B | 27.66M | 180.19M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | -17K | -2.99M | 0 | -200M | 0 | 0 | -6.74M | 0 |
| Other Financing | -1.61M | 0 | 0 | 11.87M | 0 | -14.74M | 0 | -303K |
| Net Change in Cash | 74.69M | -20.15M | 79.53M | -393.35M | -547.14M | 915.73M | -6.52M | 67.38M |
| Free Cash Flow | -31.07M | -119M | -71.03M | -187.01M | -163.47M | -161.59M | -55.55M | -107.77M |
| FCF Margin % | -0.52% | -2.01% | -1.17% | -4.33% | -6.84% | -10.62% | -4.56% | -13.57% |
| FCF Growth % | 68.46% | -67.55% | 62.02% | -14.4% | -1.17% | -190.86% | 48.45% | - |
| FCF per Share | -1.76 | -7.19 | -4.32 | -11.43 | -10.01 | -10.83 | -3.61 | -7.02 |
| FCF Conversion (FCF/Net Income) | 0.29x | 0.26x | 0.22x | 0.59x | 1.23x | 0.36x | 0.89x | 0.37x |
| Interest Paid | 1.23M | 0 | 4.6M | 5.8M | 3.67M | 4.82M | 7.09M | 0 |
| Taxes Paid | 650K | 0 | 1.8M | 5.36M | 5.31M | 1.82M | 2K | 0 |
Quick answers to the most common questions about buying AGL stock.
Agilon Health, Inc. (AGL) generated $-105.8M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Agilon Health, Inc. (AGL) reported negative free cash flow of $119.0M in 2025, indicating capital requirements exceeded cash from operations.
Agilon Health, Inc. (AGL) spent $13.2M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
In 2025, Agilon Health, Inc. (AGL) spent $3.0M on share repurchases. This shows the company's commitment to returning capital to its equity investors.
Key Metrics
Top Statement Risk
Operating cash flow volatility and medical cost pressure
Metrics are mathematically derived from official filings.
Operating Cash Conversion Remains Erratic
Based on AGL's reported quarterly figures, operating cash flow to net income ratios swung from -3.19 to 1.43 across recent quarters, a range too wide to establish a reliable earnings-to-cash conversion pattern for the business.
The conversion ratio is distorted by the presence of net losses in several quarters, which mechanically produces misleading ratios when the denominator is negative. The latest quarter's 1.43 ratio appears favorable, but it follows a quarter with operating cash outflow of $57.3M despite positive net income of $18.0M, which suggests working capital timing is driving much of the variance. Investors should monitor whether operating cash flow stays positive across multiple consecutive quarters before concluding that cash generation has structurally improved.
Free Cash Flow Turned Positive Only Recently
As reported in AGL's cash flow statements, free cash flow was negative in most of the ten quarters shown, with the latest quarter delivering $46.6M and a 3.1% margin that remains a single-quarter data point.
Across the window, free cash flow ran negative in roughly seven of ten quarters, with the deepest outflow of $60.7M occurring in the most recent full quarter before the latest print. The positive result in the latest period is heavily influenced by a $114.0M working capital reversal in the prior quarter and a $82.7M working capital inflow in 2025Q4, implying the cash result is partly timing-driven rather than purely operational. Until positive FCF persists without large working capital swings, the trajectory should be treated as unproven.
Working Capital Swings Dominate Cash Results
Based on AGL's reported figures, working capital changes ranged from a -$114.0M outflow to a +$105.8M inflow across recent quarters, magnitudes that exceed the company's reported net income in several periods and dominate the cash outcome.
Such large and alternating working capital movements are consistent with the timing of medical claims payables and IBNR-related accruals rather than steady collection or payment patterns. When working capital flows are this volatile relative to earnings, reported cash flow becomes a weak indicator of underlying operating performance. Investors should track whether these swings reverse over time, since persistent one-directional movements would raise questions about the accuracy of accrual estimates.
Asset-Light Model Limits Capital Needs
According to reported cash flow data, AGL's capital expenditures remained between roughly 0.2% and 1.2% of revenue, indicating a very light capital base that keeps investment needs modest relative to the business scale.
Capex has been consistently small, with the exception of a $14.4M inflow in 2024Q3 that likely reflects a disposal or reclassification rather than negative investment. Depreciation and amortization of roughly $6M to $7M per quarter exceeds capex in most periods, suggesting the company is not currently reinvesting heavily in its physical or technology base. This favors free cash flow conversion over time, though low investment may also reflect limited build-out of the platform relative to its growth ambitions.
Stock Compensation Inflates Cash Picture
Based on AGL's reported figures, stock-based compensation of $6.3M to $23.8M per quarter is added back in operating cash flow, meaning a portion of reported cash generation reflects non-cash equity expense rather than economic cash earnings.
Because SBC is a non-cash charge, it lifts operating cash flow relative to net income, and in periods where net income was negative this adjustment may partly offset losses in the cash presentation. Investors should consider whether the cash-based view flatters performance, particularly given the company's continued losses at the operating level. Evaluating free cash flow net of SBC would provide a more conservative picture of cash generation.